SCHEMBL614067

SCHEMBL614067

CN(C)CCOc1cccc(Nc2nc3ccc(-c4cc(O)ccc4Cl)cn3n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 6/20 0.47
LRRK2 Q5S007 2/20 0.43
AGER Q15109 1/20 0.43
CHRNB2 P17787 1/20 0.42
CHRNA4 P43681 1/20 0.42
PDGFRB P09619 3/20 0.41
YES1 P07947 2/20 0.41
PLK1 P53350 1/20 0.40
JAK2 O60674 1/20 0.40
ESR1 P03372 2/20 0.39
ESR2 Q92731 1/20 0.39
EGFR P00533 1/20 0.38
FGFR1 P11362 2/20 0.38
FGFR2 P21802 1/20 0.38
FGFR4 P22455 1/20 0.38
FGFR3 P22607 1/20 0.38
SYK P43405 1/20 0.38
TTK P33981 1/20 0.38
IGF1R P08069 1/20 0.37
CIT O14578 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL613798 0.91 ESR1 (0.45) SRCLRRK2PDGFRBYES1PLK1
SCHEMBL614557 0.85 SRC (0.63) SRCPDGFRBYES1JAK2ESR1
SCHEMBL613791 0.84 SRC (0.42) SRCLRRK2JAK2SYKTTK
SCHEMBL612666 0.83 SRC (0.55) SRCPDGFRBYES1JAK2EGFR
SCHEMBL612376 0.81 SRC (0.46) SRCLRRK2PDGFRBYES1JAK2
SCHEMBL613388 0.80 LRRK2 (0.47) SRCLRRK2PDGFRBJAK2EGFR
SCHEMBL613040 0.78 LRRK2 (0.52) SRCLRRK2PDGFRBYES1JAK2
SCHEMBL41009 0.78 LRRK2 (0.47) SRCLRRK2PDGFRBJAK2TTK
SCHEMBL615192 0.77 LRRK2 (0.48) SRCLRRK2PDGFRBYES1JAK2
SCHEMBL41122 0.76 SRC (0.53) SRCLRRK2PDGFRBJAK2TTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041195-A1 Heterocyclic compounds FOVEA PHARMACEUTICALS 2012-02-16 US claimed
US-20120041195-A1 Heterocyclic compounds FOVEA PHARMACEUTICALS 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041195-A1 Heterocyclic compounds MAP3K1, MAP3K5, MAP3K2 SRC 1204/4885LRRK2 391/4885AGER 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.